OAF, and may offer novel therapeutic targets. Small diameter (<6 mm), bioabsorbable, arterial, tissue-engineered vascular grafts (TEVGs) remain limited by thromboembolism. The objective of this study was to test whether heparin-eluting (HE) TEVGs prevent early thrombosis in a large animal model. TEVGs were created with an outer poly-ε-caprolactone electrospun nanofiber layer, with a 15-μm average pore size and an inner layer composed of a 5050 poly(L-lactide-co-ε-caprolactone) copolymer. Adult female sheep (n= 5) underwent bilateral carotid artery interposition grafting, with a control TEVG in 1 carotid artery and an HE TEVG in the contralateral position. Animals were followed for 8 weeks with weekly Duplex ultrasonography to monitor TEVG performance. All sheep survived to the designated endpoint. At 8 weeks all 5 HE TEVGs were patent. Three of 5 control TEVGs had early thrombotic occlusion at <1 week. More than 97% of heparin release occurred within the first 24 hours. Histologic evaluation of the HE TEVG displayed cellularity like a native carotid artery with no evidence of calcification. Significantly fewer platelets adhered to the HE TEVG than to the control TEVG (P < .001). This study suggests HE TEVGs prevent acute graft thrombosis. We hypothesize that the HE properties of the HE TEVG during vascular endothelialization is useful for maintaining TEVG patency. This technique may aid in the translation of small arterial TEVGs to the clinic. This study suggests HE TEVGs prevent acute graft thrombosis. We hypothesize that the HE properties of the HE TEVG during vascular endothelialization is useful for maintaining TEVG patency. This technique may aid in the translation of small arterial TEVGs to the clinic. Multiple techniques exist for the repair of supravalvular aortic stenosis (SVAS), but due to the lesion's rarity, analyses comparing the efficacy of each repair have been limited. A retrospective review of all children at a single institution who underwent repair of SVAS from June 1995 to May 2019 was performed. Anatomic and physiologic measurements across time points were compared between two predominant surgical techniques. Time-to-event outcomes were compared using the log-rank test. SVAS was repaired in 89 patients, using a single-patch in 31 (35%) and Doty repair in 58 (65%). Median age at operation was 2.5 years (IQR 1.0-6.8) with median follow-up of 5.8 years (IQR 1.8-10.7). Reoperation was required in 8 (9%) patients at a median of 1.5 years post-operative (IQR 0.3-4.8). There was one death following multiple reinterventions. The change from pre-operative to post-operative sinotubular junction z-score was greater for patients after Doty repair (median change +2.5; IQR 1.5, 4.1) than for patients after single-patch repair (median change +0.8; IQR -0.1, 2.1; p=0.001). Freedom from reoperation was longer for patients following Doty repair than the single-patch technique (p=0.008). The Doty repair provides longer freedom from reoperation following supravalvular aortic stenosis repair compared to a single-patch technique, likely through a greater increase in the sinotubular junction at the time of initial operation. The Doty repair provides longer freedom from reoperation following supravalvular aortic stenosis repair compared to a single-patch technique, likely through a greater increase in the sinotubular junction at the time of initial operation. Early coronary ischemic events are uncommon after cardiac surgery, with little known about their management or associated outcomes. We evaluated clinical outcomes of patients undergoing coronary angiography (CAG)±percutaneous coronary intervention (PCI) or redo-coronary artery bypass grafting (redo-CABG) for suspected coronary ischemia within 3 weeks of index cardiac surgery. This is a retrospective observational study based on data from 53,287 patients who underwent cardiac surgery at our institution (1996-2017). 180 patients (0.34%) satisfied the inclusion criteria. The primary outcome was 1-year all-cause mortality. Statistical evaluation involved chi-square, ANOVA, Kaplan-Meier, and ROC analyses. Most of the CAG+/-PCI and redo-CABG procedures occurred in the first 2 weeks after index cardiac surgery. Patients presenting with STEMI/NSTEMI had the lowest 1-year mortality (13.5%), followed by patients with ventricular tachycardia/fibrillation (VT/VF) (28.1%), and worst in patients with non-VT/VF arrestth overt signs/symptoms of myocardial ischemia following index cardiac surgery, TnT is not a reliable marker of underlying coronary or graft obstruction, but is a robust predictor of 1-year mortality. The risks of ascending aortic dilation and indications for intervention in pediatric patients are unclear. Given the concern for aortic size mismatch with growth, larger ascending aortic diameters have been accepted in pediatric patients. The purpose of this study was to evaluate the effectiveness of ascending aortic reduction at the time of aortic valve surgery and its effect on recurrent aortic regurgitation. A retrospective 8-year observational review (2010-2018) was conducted in pediatric patients with dilated ascending aorta undergoing aortic valve surgery at a single institution. Forty-seven patients underwent ascending aortoplasty during aortic valve surgery, of which 39 patients with complete data points had preoperative mean ascending aortic Z-scores of 5.35 ± 1.52 reduced to 1.22 ± 1.63 (P < .001) postoperatively. Ascending aortic Z-scores remained similar at 1.37 ± 1.72 at latest follow-up (P= .306). In contrast our matched control group (n= 39) without ascending aortoplasty had preoperatigrowth. The stentless porcine aortic root prosthesis (SPAR) has been described as a suitable valve for right ventricular outflow tract reconstruction (RVOTR). Indiana University Methodist Hospital in Indianapolis, Indiana began using this valve for RVOTR in 1998. This study reports medium-term to late- term outcomes of the valve in the pulmonary position. A retrospective chart review was conducted of patients older than 18 years of age who underwent RVOTR with a SPAR between April 2000 and October 2019. Primary outcomes included survival and freedom from any valvular reintervention. Secondary outcomes included endocarditis and conduit dysfunction detected by routine echocardiography or cardiac magnetic resonance imaging. A total of 135 patients underwent RVOTR with a SPAR at a median age of 32.4 years (range, 18 to 71 years). Of these patients, 129 had previous surgery. Indications included pulmonary insufficiency (90.4%), stenosis (34.8%), endocarditis (7.4%), and carcinoid (4.4%). https://www.selleckchem.com/products/crenolanib-cp-868596.html Median follow-up was 2.97 years (interquartile range, 0.